スモンの発症とCYP2D6及びCYP2C19の遺伝子多型の関連性

概要

論文の詳細を見る
We analyzed the CYP2D6 and CYP2C19 genotypes from 5 patients with a diagnosis of subacute myelo-optico-neuropathy (SMON) after the informed consent was obtained. No homozygous poor metabolizer (PM) genotype reported to be associated with Parkinson's disease (PD) was found in the present cases. The mutation located at the Hha I site of the CYP2D6 speculated to be associated with PD was found heterozygously in only one case. As for CYP2C19,no mutant homozygous genotype which was reported to be associated with the low metabolism of mephenytoin was found. And a mutant ml allele was found heterozygously in two cases, and a mutant m2 allele in the one case. There was no significant relationship between SMON and these polymorphisms of CYP2D6 and CYP2C19. These results suggest that the poor metabolizer/extensive metabolizer (PM/EM) polymorphisms of CYP2D6 and CYP2C19 may not be useful molecular markers for predicting the onset of SMON.
社団法人日本薬学会の論文
1997-12-31